UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 19, 2020
|
SECOND SIGHT MEDICAL PRODUCTS, INC. |
|
|
(Exact Name of Registrant as Specified in Its Charter) |
|
|
California |
|
|
(State or Other Jurisdiction of Incorporation) |
|
|
|
|
|
001-36747 |
02-0692322 |
|
(Commission File Number) |
(IRS Employer Identification No.) |
|
12744 San Fernando Road, Suite 400 |
|
|
|
|
|
(Address of Principal Executive Offices) |
|
|
|
|
|
(818) 833-5000 |
|
|
(Registrant's Telephone Number, Including Area Code) |
|
|
(Former Name or Former Address, if Changed Since Last Report) |
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ⎕
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ⎕
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Common Stock |
|
EYES |
|
Nasdaq |
|
|
Warrants |
|
EYESW |
|
Nasdaq |
|
|
|
-1- |
|
|
|
|
|
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On March 19, 2020, Second Sight Medical Products, Inc. (the “Company”) issued a press release announcing its financial and operating results for the three-months and year ended December 31, 2019. A copy of the Company’s press release entitled “Second Sight Reports Fourth Quarter and Full Year 2019 Financial Results” is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
ITEM 7.01. REGULATION FD DISCLOSURE
On March 19, 2020, the Company issued the press release described above in Item 2.02 of this Current Report on Form 8-K. A copy of the press release is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item shall not be deemed “filed” for the purpose of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release issued March 19, 2020 “Second Sight Reports Fourth Quarter and Full Year 2019 Financial Results” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SECOND SIGHT MEDICAL PRODUCTS, INC.
|
/s/ John T. Blake |
By: John T. Blake
|
|
-2- |
|
|
|
|
|